PALO ALTO, Calif. - Scilex Holding Company (NASDAQ:SCLX), a firm specializing in non-opioid pain management solutions, announced today the introduction of co-pay assistance programs aimed at reducing out-of-pocket expenses for commercially insured patients using its products ZTlido® and ELYXYB®. Eligible patients may now pay as little as $0, with a cap set at $25 monthly for Scilex's postherpetic neuralgia treatment ZTlido® and its migraine solution ELYXYB®.
The company's initiative is designed to improve patient access to these treatments by mitigating financial barriers. Scilex emphasizes the importance of affordability in healthcare, particularly for patients requiring ongoing pain management. The co-pay programs are part of Scilex's broader effort to support patients in need of their medications without the burden of high deductibles and co-pays.
In a related move, as of April 1, 2024, ELYXYB® has been included in the purchasing pool of a multi-state Medicaid pharmaceutical group, expanding its availability to Medicaid programs across thirteen states. This expansion is expected to further enhance patient access to ELYXYB®.
Scilex's portfolio also includes Gloperba®, an anti-gout medication that is anticipated to launch in the first half of 2024. Additionally, the company has several product candidates in various stages of clinical development, including SP-102, SP-103, and SP-104, which are being explored for conditions such as sciatica, chronic neck pain, and fibromyalgia.
This article is based on a press release statement from Scilex Holding Company.
InvestingPro Insights
Scilex Holding Company (NASDAQ:SCLX) has recently taken steps to improve the affordability and accessibility of its pain management solutions. While these initiatives are poised to enhance patient care, it's important for investors to consider the company's financial health and market performance. According to InvestingPro data, Scilex operates with a market capitalization of $147.51 million and has experienced a revenue growth of 22.9% over the last twelve months as of Q4 2023. Despite these positive indicators, the company's significant debt burden and a P/E ratio of -0.93 reflect challenges in profitability.
InvestingPro Tips suggest that Scilex may encounter difficulties making interest payments on its debt, and analysts do not anticipate the company will be profitable this year. Moreover, the stock has taken a substantial hit over the last week, with a price total return of -10.32%. These financial challenges are compounded by the fact that the company's short-term obligations exceed its liquid assets, signaling potential liquidity issues.
Nevertheless, analysts do anticipate sales growth in the current year, which could provide a silver lining for the company's prospects. It's also noteworthy that Scilex does not pay a dividend to shareholders, which is a common practice for companies focused on reinvesting earnings into growth and development.
For investors looking to delve deeper into Scilex's financials and future outlook, InvestingPro offers comprehensive analysis and additional tips. There are currently 6 more InvestingPro Tips available for Scilex, which can be accessed at https://www.investing.com/pro/SCLX. To obtain an additional 10% off a yearly or biyearly Pro and Pro+ subscription, use the coupon code PRONEWS24.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.